What is the dosing range for KPV?

KPV is typically dosed at 250mcg (low), 500mcg (moderate), or 1000mcg (high) mcg, administered Once or twice daily. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of KPV?

Reported side effects of KPV include: Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH).

Healing

KPV

Also known as: Lys-Pro-Val, Alpha-MSH C-terminal tripeptide

KPV is a research compound not approved for human use. For informational purposes only.

📚 Content aggregated from:3 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.

Research Summary

KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.

Dosing Range

low

250mcg

moderate

500mcg

high

1000mcg

Units: mcg · Frequency: Once or twice daily

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injectionOral (encapsulated — for gut-specific delivery)Intranasal

Reconstitution Notes

Reconstitute with bacteriostatic water to 1mg/mL. For oral delivery, KPV can be encapsulated in enteric-coated capsules or mixed with a small amount of water and taken on an empty stomach. Stable 28 days refrigerated.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Generally well-tolerated
Mild injection site irritation
Transient headache (uncommon)
No melanogenic effects (does not cause tanning unlike full α-MSH)

Research Papers

3 peer-reviewed sources

Alpha-MSH tripeptide analogue KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine expression

Journal of Leukocyte Biology1999

The melanocortin peptide KPV has anti-inflammatory effects in colitis

Peptides2006

Oral peptide therapy targeting gut mucosa: KPV loaded nanoparticles for colitis treatment

Gastroenterology2010

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Peptides

Community reports on KPV for IBD, Crohn's, colitis, and leaky gut protocols — often combined with BPC-157.

View original thread

Overview

KPV stands for Lysine-Proline-Valine — the three C-terminal amino acids of alpha-MSH. While the full 13-amino acid α-MSH sequence activates melanin production (causing tanning), KPV retains the anti-inflammatory core without this effect. This makes it uniquely useful for gut inflammation research where systemic melanogenic side effects would be undesirable.

Why the Gut?

KPV is unusual among peptides in that oral delivery is viable. Most peptides are destroyed by stomach acid and digestive enzymes. KPV's small tripeptide structure survives gastric transit sufficiently to reach the intestinal mucosa, where it exerts local anti-inflammatory effects. When loaded into nanoparticle delivery systems, oral efficacy is significantly enhanced.

The gut mucosa expresses high levels of MC1R and MC3R — the receptors KPV activates — making the intestinal epithelium a primary target for its anti-inflammatory signaling.

Mechanism

KPV reduces gut inflammation through multiple pathways:

NF-κB inhibition — directly suppresses the master inflammatory transcription factor
Cytokine reduction — lowers TNF-α, IL-1β, and IL-8 in inflamed tissue
Neutrophil trafficking — reduces neutrophil infiltration into colonic tissue
Epithelial barrier — supports tight junction protein expression and barrier repair

These mechanisms overlap significantly with BPC-157, making the two peptides synergistic for gut healing protocols.

KPV + BPC-157 Stack

Commonly researched together:

BPC-157: Systemic healing, angiogenesis, gut-brain axis repair
KPV: Local anti-inflammatory at the mucosal level

Typical approach: BPC-157 injected systemically; KPV taken orally (encapsulated) to act directly on the gut lining. This combination addresses both systemic and local inflammation in IBD/leaky gut models.

IBD Research Context

Animal models of colitis (DSS-induced, TNBS-induced) consistently show KPV reduces disease activity index, crypt damage, and inflammatory infiltrate. While human clinical trials are not yet complete, the mechanistic rationale and animal data are among the strongest of any peptide studied for IBD.